Through transcriptomic analysis of human brain samples from both PART and AD patients, combined with in vivo and in vitro validation, we identified PRMT3 as a key driver of tau hyperphosphorylation in the EC region of PART patients. The gene discussed is MAPT; the disease is Alzheimer disease.